Matches in Wikidata for { <http://www.wikidata.org/entity/Q91516833> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q91516833 description "article scientifique publié en 2019" @default.
- Q91516833 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q91516833 description "im April 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91516833 description "scientific article published on 26 April 2019" @default.
- Q91516833 description "wetenschappelijk artikel" @default.
- Q91516833 description "наукова стаття, опублікована 26 квітня 2019" @default.
- Q91516833 name "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 name "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 type Item @default.
- Q91516833 label "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 label "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 prefLabel "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 prefLabel "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 P1433 Q91516833-37B1FE5B-1C5F-43FB-84AF-33AF6FAF2C50 @default.
- Q91516833 P1476 Q91516833-C6472B62-3E3E-4A28-B8DE-877E2C24E253 @default.
- Q91516833 P2093 Q91516833-127C62D9-BC06-47DE-A269-531566C0D92C @default.
- Q91516833 P2093 Q91516833-3C98FF1E-3A1B-44D0-B2DD-5AB143C7CE64 @default.
- Q91516833 P2093 Q91516833-41E408DF-9E6A-48F9-BB08-AD9EF5988C29 @default.
- Q91516833 P2093 Q91516833-47DA7B4D-4F9B-4C50-8092-C9717CD0E6EC @default.
- Q91516833 P2093 Q91516833-96EE7B2F-055D-4ED0-B35C-33A186583693 @default.
- Q91516833 P2093 Q91516833-AEC38024-A96B-4973-93D1-26CC5C58B5E8 @default.
- Q91516833 P2093 Q91516833-DAB2E9EF-0017-4229-A502-EB5BE079ACA3 @default.
- Q91516833 P2093 Q91516833-E9B41A0E-D759-476B-8BD3-534B8FB6CD92 @default.
- Q91516833 P2093 Q91516833-EC4A2FCA-7E0B-43C8-91A7-20606E3B955C @default.
- Q91516833 P2093 Q91516833-FF53A8D7-38B1-4A2E-9462-750768D16565 @default.
- Q91516833 P304 Q91516833-2DB3D59C-490F-40E9-BACD-D1A27B3B857C @default.
- Q91516833 P31 Q91516833-B7D8B040-E19A-4261-96D1-A5E0DB6DC31C @default.
- Q91516833 P356 Q91516833-4DE74292-29BE-4D11-B602-59D614BA7C56 @default.
- Q91516833 P433 Q91516833-58D5EDF0-2806-412C-A2EF-17C4F8F6804D @default.
- Q91516833 P478 Q91516833-DFDFB10F-2B30-47DC-8ADD-518B0696AC46 @default.
- Q91516833 P50 Q91516833-5302B983-3A7D-48A6-AAEC-578A6DAED59E @default.
- Q91516833 P50 Q91516833-BB12B12A-E17F-4AAC-BFF6-EF5568545950 @default.
- Q91516833 P577 Q91516833-127ECACB-03BB-47C4-9B49-E816AD515565 @default.
- Q91516833 P698 Q91516833-2B9BFB3C-F806-40BB-AA7C-9A45F17DDCB9 @default.
- Q91516833 P921 Q91516833-949E74CA-BB6A-4B9F-83FC-962EBC86CE1B @default.
- Q91516833 P921 Q91516833-FE273B6D-1BE6-4C3D-900D-F2BF8EDA9657 @default.
- Q91516833 P356 FON-2019-0111 @default.
- Q91516833 P698 31023100 @default.
- Q91516833 P1433 Q2781597 @default.
- Q91516833 P1476 "A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)" @default.
- Q91516833 P2093 "Axel Bex" @default.
- Q91516833 P2093 "Brunolf Lagerveld" @default.
- Q91516833 P2093 "Jeroen A van Moorselaar" @default.
- Q91516833 P2093 "Johan V van Thienen" @default.
- Q91516833 P2093 "Kees Hendricksen" @default.
- Q91516833 P2093 "Mariette Schrier" @default.
- Q91516833 P2093 "Niels Graafland" @default.
- Q91516833 P2093 "Patricia Zondervan" @default.
- Q91516833 P2093 "Sofie Wilgenhof" @default.
- Q91516833 P2093 "Teele Kuusk" @default.
- Q91516833 P304 "2203-2209" @default.
- Q91516833 P31 Q13442814 @default.
- Q91516833 P356 "10.2217/FON-2019-0111" @default.
- Q91516833 P433 "19" @default.
- Q91516833 P478 "15" @default.
- Q91516833 P50 Q86605268 @default.
- Q91516833 P50 Q89370036 @default.
- Q91516833 P577 "2019-04-26T00:00:00Z" @default.
- Q91516833 P698 "31023100" @default.
- Q91516833 P921 Q1164529 @default.
- Q91516833 P921 Q42824440 @default.